PT1729813E - Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo - Google Patents
Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo Download PDFInfo
- Publication number
- PT1729813E PT1729813E PT05744579T PT05744579T PT1729813E PT 1729813 E PT1729813 E PT 1729813E PT 05744579 T PT05744579 T PT 05744579T PT 05744579 T PT05744579 T PT 05744579T PT 1729813 E PT1729813 E PT 1729813E
- Authority
- PT
- Portugal
- Prior art keywords
- piroxicam
- cyclodextrin
- arginine
- complex
- complexes containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0403450A FR2868315B1 (fr) | 2004-04-01 | 2004-04-01 | Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique |
| FR0411201A FR2876911B1 (fr) | 2004-10-21 | 2004-10-21 | Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1729813E true PT1729813E (pt) | 2011-07-12 |
Family
ID=34968371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05744579T PT1729813E (pt) | 2004-04-01 | 2005-03-29 | Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo |
| PT101820892T PT2260871E (pt) | 2004-04-01 | 2005-03-29 | Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente para interação com o complexo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT101820892T PT2260871E (pt) | 2004-04-01 | 2005-03-29 | Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente para interação com o complexo |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8461133B2 (pt) |
| EP (2) | EP1729813B1 (pt) |
| JP (1) | JP5091661B2 (pt) |
| AR (1) | AR049488A1 (pt) |
| AT (1) | ATE504316T1 (pt) |
| BR (1) | BRPI0509482B1 (pt) |
| CA (1) | CA2563101C (pt) |
| CY (1) | CY1114198T1 (pt) |
| DE (1) | DE602005027333D1 (pt) |
| DK (1) | DK2260871T3 (pt) |
| ES (1) | ES2424235T3 (pt) |
| PL (2) | PL1729813T3 (pt) |
| PT (2) | PT1729813E (pt) |
| RU (1) | RU2382654C2 (pt) |
| SI (1) | SI2260871T1 (pt) |
| WO (1) | WO2005097201A2 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2876914A1 (fr) * | 2004-10-21 | 2006-04-28 | Pierre Fabre Medicament Sa | Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction |
| FR2876910B1 (fr) * | 2004-10-21 | 2007-04-13 | Pierre Fabre Medicament Sa | Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction |
| FR2914187B1 (fr) * | 2007-03-28 | 2011-01-21 | Pf Medicament | Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique. |
| US20120171184A1 (en) | 2010-12-31 | 2012-07-05 | Lajos Szente | Cellular hydration compositions |
| KR101383941B1 (ko) | 2012-03-09 | 2014-04-10 | 동아에스티 주식회사 | 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법 |
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| CN109142420B (zh) * | 2018-10-12 | 2020-01-10 | 厦门大学 | 基于核磁共振技术探究药物在胶束内最大增溶量的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434163A (en) | 1981-06-01 | 1984-02-28 | Pfizer Inc. | Water-soluble benzothiazine dioxide salts |
| IT1196033B (it) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| JPS632929A (ja) * | 1986-06-20 | 1988-01-07 | Kao Corp | アセチルサリチル酸製剤 |
| CA1321192C (en) * | 1988-04-20 | 1993-08-10 | Abdul Majid | Inclusion complexes of cyclodextrins by agglomeration |
| KR920006911B1 (ko) * | 1989-06-14 | 1992-08-22 | 신풍제약 주식회사 | 안정한 피록시캄 주사액 조성물 및 그의 제조방법 |
| IT1241088B (it) | 1990-03-27 | 1993-12-29 | Chiesi Farma Spa | Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche |
| WO1992003048A1 (en) * | 1990-08-13 | 1992-03-05 | Commonwealth Scientific And Industrial Research Organisation | Pesticidal products |
| EP1004318A3 (en) * | 1991-06-21 | 2002-08-07 | Takeda Chemical Industries, Ltd. | Cyclodextrin composition |
| AT400674B (de) | 1991-07-24 | 1996-02-26 | Biochemie Gmbh | Pharmazeutische pleuromutilin-zubereitung |
| IT1293764B1 (it) | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
| ES2149750T3 (es) | 1999-01-06 | 2004-06-01 | Tecnimede-Sociedade Tecnico-Medicinal, S.A. | Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos. |
| FR2815540B1 (fr) | 2000-10-19 | 2005-06-10 | Separex Sa | Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote |
| WO2002089851A1 (fr) * | 2001-03-06 | 2002-11-14 | Separex (Societe Anonyme) | Procede de fabrication de complexes hote-client |
| FR2830760B1 (fr) * | 2001-10-12 | 2004-06-04 | Pf Medicament | Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique |
| FR2830761B1 (fr) | 2001-10-12 | 2003-12-12 | Pf Medicament | Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique |
| RU2004123612A (ru) * | 2002-01-15 | 2005-04-20 | ЮСиБи ФАРШИМ С.А. (CH) | Фармацевтическая композиция для перорального применения |
| ATE359827T1 (de) * | 2002-06-17 | 2007-05-15 | Chiesi Farma Spa | Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe |
| FR2854079B1 (fr) * | 2003-04-25 | 2007-11-30 | Pf Medicament | Procede de preparation de complexes moleculaires |
| WO2005112637A1 (en) * | 2004-05-14 | 2005-12-01 | Decode Chemistry, Inc. | Formulations for non-parenteral use including hydrophobic cyclodextrins |
-
2005
- 2005-03-29 PL PL05744579T patent/PL1729813T3/pl unknown
- 2005-03-29 PT PT05744579T patent/PT1729813E/pt unknown
- 2005-03-29 DK DK10182089.2T patent/DK2260871T3/da active
- 2005-03-29 SI SI200531739T patent/SI2260871T1/sl unknown
- 2005-03-29 US US10/594,740 patent/US8461133B2/en not_active Expired - Fee Related
- 2005-03-29 WO PCT/FR2005/000739 patent/WO2005097201A2/fr active Application Filing
- 2005-03-29 RU RU2006138488/15A patent/RU2382654C2/ru not_active IP Right Cessation
- 2005-03-29 ES ES10182089T patent/ES2424235T3/es active Active
- 2005-03-29 EP EP05744579A patent/EP1729813B1/fr not_active Not-in-force
- 2005-03-29 BR BRPI0509482A patent/BRPI0509482B1/pt not_active IP Right Cessation
- 2005-03-29 CA CA2563101A patent/CA2563101C/fr not_active Expired - Fee Related
- 2005-03-29 PL PL10182089T patent/PL2260871T3/pl unknown
- 2005-03-29 AT AT05744579T patent/ATE504316T1/de not_active IP Right Cessation
- 2005-03-29 EP EP10182089.2A patent/EP2260871B1/fr not_active Not-in-force
- 2005-03-29 JP JP2007505584A patent/JP5091661B2/ja not_active Expired - Fee Related
- 2005-03-29 DE DE602005027333T patent/DE602005027333D1/de active Active
- 2005-03-29 PT PT101820892T patent/PT2260871E/pt unknown
- 2005-04-01 AR ARP050101306A patent/AR049488A1/es unknown
-
2013
- 2013-04-30 US US13/873,959 patent/US9243076B2/en not_active Expired - Fee Related
- 2013-08-07 CY CY20131100671T patent/CY1114198T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005097201A2 (fr) | 2005-10-20 |
| PL1729813T3 (pl) | 2011-09-30 |
| EP2260871B1 (fr) | 2013-05-15 |
| EP2260871A3 (fr) | 2011-05-18 |
| EP2260871A2 (fr) | 2010-12-15 |
| JP5091661B2 (ja) | 2012-12-05 |
| RU2006138488A (ru) | 2008-05-10 |
| BRPI0509482A (pt) | 2007-09-11 |
| CA2563101C (fr) | 2013-07-02 |
| BRPI0509482B1 (pt) | 2018-12-11 |
| WO2005097201A3 (fr) | 2006-08-17 |
| EP1729813A2 (fr) | 2006-12-13 |
| CY1114198T1 (el) | 2016-08-31 |
| PL2260871T3 (pl) | 2013-10-31 |
| ATE504316T1 (de) | 2011-04-15 |
| EP1729813B1 (fr) | 2011-04-06 |
| ES2424235T3 (es) | 2013-09-30 |
| SI2260871T1 (sl) | 2013-09-30 |
| US20070270379A1 (en) | 2007-11-22 |
| AR049488A1 (es) | 2006-08-09 |
| PT2260871E (pt) | 2013-08-01 |
| DK2260871T3 (da) | 2013-08-26 |
| US8461133B2 (en) | 2013-06-11 |
| US9243076B2 (en) | 2016-01-26 |
| CA2563101A1 (fr) | 2005-10-20 |
| US20130316975A1 (en) | 2013-11-28 |
| DE602005027333D1 (de) | 2011-05-19 |
| RU2382654C2 (ru) | 2010-02-27 |
| JP2007530641A (ja) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1729813E (pt) | Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo | |
| Shao et al. | Cyclodextrins as nasal absorption promoters of insulin: mechanistic evaluations | |
| Tengamnuay et al. | Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts | |
| Koc et al. | Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats | |
| JP2008526757A5 (pt) | ||
| RS20060169A (en) | Process for preparing water soluble diterpens and their applications | |
| WO2007125501A3 (en) | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness | |
| AR053737A1 (es) | Formulacion pediatrica de topiramato | |
| HK1082430A1 (en) | Method for the preparation of molecular complexes | |
| JP2003063965A (ja) | 注射用シロスタゾール水性製剤 | |
| Anconi et al. | Inclusion complexes of α-cyclodextrin and the cisplatin analogues oxaliplatin, carboplatin and nedaplatin: A theoretical approach | |
| Tomita et al. | Amperometric biosensor for ascorbic acid | |
| Irwin et al. | The effect of cyclodextrins on the stability of peptides in nasal enzymic systems | |
| Muraoka et al. | Evaluation of the bioavailability of flurbiprofen and its β-cyclodextrin inclusion complex in four different doses upon oral administration to rats | |
| Roberts et al. | Differential chemoprotection against acetaminophen-induced hepatotoxicity by latentiated L-cysteines | |
| FR2892307B1 (fr) | Compositions cosmetiques contenant un ester, un polymere acrylique, une cyclodextrine et un tensioactif et leurs utilisations | |
| Tokumura et al. | Improvement of oral bioavailability of flurbiprofen from flurbiprofen/β-cyclodextrin inclusion complex by action of cinnarizine | |
| Maruthanayagam et al. | Haemato-biochemical variations induced by the pesticide, monocrotophos in Cyprinus carpio during the exposure and recovery periods | |
| Lin et al. | Chiral separation of hydroxyflavanones in cyclodextrin-modified capillary zone electrophoresis using sulfated cyclodextrins as chiral selectors | |
| Ma et al. | Dipeptide-Capped Copper Nanoparticles as Chiral Nanozymes for Colorimetric Enantioselective Recognition of 3, 4-Dihydroxy-d, l-phenylalanine | |
| JP5157447B2 (ja) | メキタジンとシクロデキストリンと相互作用剤を含む複合体 | |
| WO2007010285A3 (en) | Crystal structure of human soluble adenylate cyclase | |
| CY1112794T1 (el) | Διαλυμα περιτοναϊκης αιμοκαθαρσης που περιεχει καρνιτινη το οποιο εχει βελτιωμενη βιοσυμβατοτητα | |
| JP6302733B2 (ja) | 腸管バリア機能亢進剤、腸疾患治療及び予防用医薬組成物 | |
| JAIN | Enhancement of intestinal absorption of few COX-2 inhibitors through interaction with β-cyclodextrin |